The EMA and US FDA say they agree on how pharmaceutical firms should include quality-by-design (QbD) elements in drug approval and manufacturing change applications, citing a recently completed pilot collaboration.

http://www.in-pharmatechnologist.com/Regulatory-Safety/EMA-and-FDA-aligned-on-how-pharmas-should-include-QbD-in-applications